ClinicalTrials.gg
Active, not recruitingNCT06073535Updated Dec 21, 2023

The Use of Injectable-Platelet Rich Fibrin (i-PRF) in the Lower Third Molar Extraction

An interventional study of Extraction of mandibular third molar and i-PRF in Molar, Third and Postoperative Complications, sponsored by University of Naples. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by University of Naples · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2023, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Postoperative Complications with a site in Italy — 16 open to participants now, 18 under way, 1 of them phase 3. Postoperative Complications · Italy.

Enrollment
30th of 35
40 · median 150
Started
2023
with 4 others
No phase
30 of 59
6 open now
Primary completion
2023-09
later than 1 of 17 live
Registered
43rd of 59
by date

Among the 59 studies in Postoperative Complications with a site in Italy, this one is the 30th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2023, is one of 30 with no phase, reaches primary completion later than 1 of the 17 other live ones, and was the 43rd registered.

Postoperative Complications

1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

16 of the 59 studies in Postoperative Complications with a site in Italy are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 200 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 31 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Postoperative Complications with a site in Italy, or all of them as a file.
02

Study summary

Lower third molar extraction is one of the most frequently performed surgical procedures in dentistry. Common sequelae, including pain, swelling and trismus, can severely affect patients' quality of life during the immediate postoperative period.

The aim of this randomized-controlled trial is to clinically evaluate the reduction of lower third molar extraction-related complications, such as swelling and pain, and wound healing, following submucosal infiltration of injectable platelet rich fibrin.

Read the detailed description

Forty young patients with a partially or totally impacted lower third molar, with an equivalent degree of difficulty, will be selected. All patients will be randomly treated by using 2 different therapeutic approaches, thereby yielding 2 different study groups, each of which is composed of 20 cases: in the first group, the extraction socket will be left healing spontaneously, while in the other side the socket will be filled with i-PRF.

This study was designed as a double-blind research since the investigator will be unaware of their treatment allocation before surgery, and one clinician, not involved in patient treatment and not aware of what therapeutic approach used for the different sites of treatment, will perform clinical measurement of the outcomes on the surgery day, 3th and 7th days after surgery.

A software will be used to produce a random sequence of 20 integer numbers without duplicates generated from atmospheric noise and concealed in closed envelopes by one of the investigators. At the time of the patient's first surgery, the envelope will be opened and patient allocated to group 1 or group 2.

Prior to surgery, photographic documentation consisting of frontal extraoral photograph, extraoral latero-lateral photograph of the surgery site, extraoral latero-lateral photograph of the opposite site will be performed.

The swelling will be measured summing two linear measurements of distance between Tragus and Pogonion and then Gonion and Commissura labialis points.

Immediately after surgery, the surgeon opens the envelope containing the information about the patient's group membership. In case of i-PRF group, 20 mL will be prepared.

Everyday after surgery, each patients will compile the visual analogic scale to evaluate the pain score.

On 3th and 7th day after surgery, linear measurements of swelling will be taken. Then, on 3th, 7th, 14th, 28th days the wound healing index by Landry will be evaluate.

The Student t test will be used to compare the differences between the two analysed groups. Potential differences between pain, swelling and wound healing based on gender, age and time of surgery will be assessed by using Student's t-test and one-way analysis of variance (ANOVA).

03

Conditions studied

  • Molar, Third
  • Postoperative Complications

Keywords

  • Molar, third
  • Postoperative complications
  • Swelling
  • Pain
  • Platelet-rich fibrin
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Need for extraction of totally or partially impacted lower third molar
  • Equivalent degree of difficulty of lower third molar extraction
  • Patients able to understand and sign

Exclusion criteria

Exclusion Criteria:

  • General for surgery (systemic disease, compromised immune system etc);
  • Tobacco smoking
  • Alcohol and drug abuse
  • Pregnancy and breastfeeding
  • Patients taking any medications which might interfere with healing
  • Dysplastic processes in the affected tooth elements
  • Non-cooperative patients

EXCLUSION CRITERIA DURING FOLLOW-UP - Patients who do not adhere throughout the duration of follow-up to the specialist visits

POSTOPERATIVE EXCLUSION CRITERIA

  • Taking more than two doses of prescribed anti-inflammatory/analgesic medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    i-PRF

    i-PRF will be used after the extraction of the third molar to reduce postoperative complications (swelling, pain) and wound healing.

    Procedure: Extraction of mandibular third molar · Device: i-PRF

  • Active comparator
    Spontaneous healing

    After the extraction of the lower third molar the socket will be left to heal spontaneously.

    Procedure: Extraction of mandibular third molar

Interventions

  • ProcedureExtraction of mandibular third molar

    After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary.

  • Devicei-PRF

    20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.

06

What researchers measure

Primary outcomes

  1. Postoperative swelling

    Measurements will be made with a flexible ruler taking as reference the diagonals joining Tragus and Pogonion; Gonion and Labial Commissura. Swelling will be calculated as the sum of these diagonals.

    Time frame: Measurements will be taken before surgery, on day 3 and day 7.

Secondary outcomes

  1. Postoperative pain

    Pain was assessed with a visual analogic scale (VAS) from 0 (absence of pain) to 10 (severe pain).

    Time frame: Everyday after surgery until 7th day.

Other outcomes

  1. Wound healing

    Landry index including description from a "Very poor" to an "Excellent" wound healing

    Time frame: Measurements will be taken on day 3, 7, 14, 28 days.

07

Study locations

1 site
  • Gilberto Sammartino
    Naples, 80131, Italy
08

References and documents

Publications

  • Sammartino G, Gasparro R, Marenzi G, Trosino O, Mariniello M, Riccitiello F. Extraction of mandibular third molars: proposal of a new scale of difficulty. Br J Oral Maxillofac Surg. 2017 Nov;55(9):952-957. doi: 10.1016/j.bjoms.2017.09.012. Epub 2017 Oct 18. PubMed 29054564 ↗
  • Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009 Feb;27(1):63-9. doi: 10.1080/08977190802636713. PubMed 19089687 ↗
  • Passaretti F, Tia M, D'Esposito V, De Pascale M, Del Corso M, Sepulveres R, Liguoro D, Valentino R, Beguinot F, Formisano P, Sammartino G. Growth-promoting action and growth factor release by different platelet derivatives. Platelets. 2014;25(4):252-6. doi: 10.3109/09537104.2013.809060. Epub 2013 Jul 15. PubMed 23855408 ↗
  • Dohan Ehrenfest DM, Bielecki T, Del Corso M, Inchingolo F, Sammartino G. Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A. 2010 Dec 15;95(4):1280-2. doi: 10.1002/jbm.a.32894. Epub 2010 Oct 5. No abstract available. PubMed 20925082 ↗
  • Farshidfar N, Jafarpour D, Firoozi P, Sahmeddini S, Hamedani S, de Souza RF, Tayebi L. The application of injectable platelet-rich fibrin in regenerative dentistry: A systematic scoping review of In vitro and In vivo studies. Jpn Dent Sci Rev. 2022 Nov;58:89-123. doi: 10.1016/j.jdsr.2022.02.003. Epub 2022 Mar 29. PubMed 35368368 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Sep 2023, 6 months.

Of 395 non-industry interventional studies with no phase under Postoperative Complications, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 6 months is below that.

Counting every sponsor, half of 399 studies reached it within 20 months; a quarter within 8 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 10, 2023
StartActual
Feb 27, 2023
Primary completionActual
Sep 4, 2023
CompletionEst.
Dec 29, 2023
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06073535
Lead sponsor
University of Naples
Responsible party
Gilberto Sammartino (Full Professor, University of Naples) — Principal investigator
First posted
Oct 10, 2023
Start date
Feb 27, 2023
Primary completion
Sep 4, 2023
Completion
Dec 29, 2023 (estimated)
Last update
Dec 21, 2023

Study contacts

Gilberto Sammartino, Professor
principal investigator · Federico II University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion